Focal Interest
Focal Interest
AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: MODERATE — reflects the venue and review process. — venue and review process.

AOH1996 remained the most active PCNA inhibitor analog

Fluorescently stained cells in culture viewed under a microscope, showing blue nuclei and green cytoplasmic structures with red organelles, displaying multiple cells at various stages across the field of view.
Research area:Biochemistry, Genetics and Molecular BiologyCancer therapeutics and mechanismsCell culture

What the study found

AOH1996, a previously reported PCNA (proliferating cell nuclear antigen) inhibitor, was the most active compound in this study. Several new AOH1996-based analogs also showed antiproliferative activity in MCF-7 breast cancer and U87 glioblastoma cell cultures.

Why the authors say this matters

The authors state that PCNA and its cancer-associated isoforms are promising therapeutic targets. They also suggest that some active compounds, especially 2b and 3b, may serve as lead scaffolds for further optimization and experimental validation.

What the researchers tested

The researchers synthesized a series of AOH1996 analogs using structure-activity relationship (SAR) and scaffold-hopping strategies, including 1,2,3-triazole, glycine, and amide derivatives with different aromatic and polar substituents. They tested antiproliferative activity with the MTT assay in MCF-7 and U87 cell lines and also used ADMET predictions to assess drug-likeness, absorption, and other properties.

What worked and what didn't

The parent compound AOH1996 reduced cell viability below 30% at 10 μM and showed the strongest cytotoxicity. Compounds 1f, 2b, 3b, 3c, and 3d were also active, reducing MCF-7 viability by 60-70% and U87 viability to 30-40% at 10 μM.

What to keep in mind

The abstract notes that most derivatives had favorable predicted drug-likeness and absorption, but also predicted limitations including high plasma protein binding, short half-lives, and potential cardiotoxicity. It also says several active compounds were predicted to inhibit P-glycoprotein, but the available summary does not describe direct experimental validation of these predictions.

Key points

  • AOH1996 showed the strongest cytotoxicity among the compounds tested.
  • Compounds 1f, 2b, 3b, 3c, and 3d also showed significant antiproliferative activity.
  • Activity was measured in MCF-7 breast cancer cells and U87 glioblastoma cells using the MTT assay.
  • The abstract reports that electron-withdrawing or moderately lipophilic substituents improved potency, while bulky or strongly electron-donating groups reduced it.
  • ADMET predictions suggested favorable drug-likeness for many derivatives, but also possible limitations such as high protein binding and potential cardiotoxicity.

Disclosure

Research title:
AOH1996 remained the most active PCNA inhibitor analog
Authors:
Simona Jonušienė, Agnė Janonienė, Mantas Jonušis, Adas Darinskas, D. Sokol
Institutions:
Vilnius University, National Cancer Institute
Publication date:
2026-03-05
DOI:
10.3390/molecules31050862
OpenAlex record:
View
AI provenance: This post was generated by OpenAI. The original authors did not write or review this post.

More posts